How effective is ivonib in treating cholangiocarcinoma?

ivosidenibis an isocitrate dehydrogenase-1 (IDH1)inhibitors, used to treat patients with IDH1gene mutations(changes< /span>)certain types of acute myeloid leukemia or cholangiocarcinoma(a type of cholangiocarcinoma).

Isocitrate dehydrogenase1 (IDH1)mutations occur in approximately13% of patients with intrahepatic cholangiocarcinoma, a relatively rare cancer with poor clinical prognosis. An international Phase 3 study is evaluating ivonib (AG-120) - a mutant form of IDH1 Efficacy and safety of 's small molecule targeted inhibitors-in patients with previously treated IDH1 mutant cholangiocarcinoma.

Methods:This multicenter, randomized, double-blind, placebo-controlled Phase 3 study included 649 hospitals aged at least18 years old with histologically confirmed advanced IDH1mutated cholangiocarcinoma in patients who have progressed on prior therapy and have received up to two previous regimens for advanced disease and have an Eastern Cooperative Oncology Group performance status score of 0 or 1 and have measurable disease as defined by the Response Evaluation Criteria in Solid Tumors version 1.1. Patients were randomly assigned (2:1), 6 to each group and stratified by the number of prior systemic regimens for advanced disease, to receive ivonib 500 mg orally once daily for 28 days.or matching placebo. Radiologic progression allowed crossover from placebo to Cedenib, based on investigator assessment. The primary endpoint was progression-free survival by independent center review. The intention-to-treat population was used for the primary efficacy analysis. Safety was assessed in all patients who received at least one dose of ivonib or placebo.

Survey results:In2017year2month20Day to2019Year1Month31Day, for23 0patients have been evaluated for eligibility, as of2019Year1month31day data As of the date, 185 patients have been randomly assigned to ivosidenib (n=124) or placebo (n=61). The median follow-up for progression-free survival was 6 9 months (IQR 2 8-10 9). Compared with the placebo group, progression-free survival was significantly longer in the ivonib group(median time was 2-7 months[95% CI 1.6-4.2] vs. 1.4months[1.4-1.6]; hazard ratio0.37 ;95%Confidence interval0.25-0.54; One-sidedp<0 0001). The most common grade 3 or worse adverse event in both treatment groups was ascites (4 in 59 patients who received placebo. span>cases[7%], and 121patients who received ivonib were 9[7%]). Of 121patients who received ivonib, 36(30%) developed severe Serious adverse events occurred in 13 of the 59 patients who received placebo (22%)Serious adverse events occurred. There were no treatment-related deaths.

Explanation:Avosidenib significantly improved progression-free survival compared with placebo and was well tolerated. This study demonstrates the clinical benefit of targeting IDH1 mutations in advanced IDH1mutant cholangiocarcinoma. If you want to get more high-quality information, you can contact Yaodede. Yaode will do its best to learn more about high-quality overseas drugs for you.